Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAmortization - Deferred ChargesCost of RevenueLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

BioXcel Therapeutics (BTAI) Amortization - Deferred Charges (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Amortization - Deferred Charges data on record, last reported at $441000.0 in Q3 2025.

  • For Q3 2025, Amortization - Deferred Charges rose 316.04% year-over-year to $441000.0; the TTM value through Sep 2025 reached $1.4 million, up 154.71%, while the annual FY2024 figure was $467000.0, 65.99% down from the prior year.
  • Amortization - Deferred Charges reached $441000.0 in Q3 2025 per BTAI's latest filing, up from $393000.0 in the prior quarter.
  • Across five years, Amortization - Deferred Charges topped out at $441000.0 in Q3 2025 and bottomed at $43000.0 in Q1 2024.
  • Average Amortization - Deferred Charges over 4 years is $274000.0, with a median of $321000.0 recorded in 2022.
  • Peak YoY movement for Amortization - Deferred Charges: crashed 87.09% in 2024, then surged 713.95% in 2025.
  • A 4-year view of Amortization - Deferred Charges shows it stood at $217000.0 in 2022, then skyrocketed by 41.47% to $307000.0 in 2023, then decreased by 27.69% to $222000.0 in 2024, then soared by 98.65% to $441000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization - Deferred Charges were $441000.0 in Q3 2025, $393000.0 in Q2 2025, and $350000.0 in Q1 2025.